Inglasia provides EU GMP Annex 16 certification services, ensuring that every medicinal product batch released into the European market meets full regulatory compliance. This service focuses on legally responsible batch certification under Annex 16, performed by experienced Qualified Persons (QPs). Every step is designed to verify that manufacturing, testing, and documentation comply with EU GMP standards, giving your business confidence that each batch is fully certified for EU market release.
Our Annex 16 certification service is compliance-driven and legally accountable. It is not import licensing, storage, distribution, or general consultancy—its sole purpose is to provide legally recognised certification of medicinal product batches. By managing this process, we ensure that your products meet EU regulatory requirements, are traceable, and are prepared for downstream commercial release or clinical supply.
Partner with Inglasia as your EU batch release partner, and benefit from our inspection-ready processes, structured documentation review, and expert QP oversight. Every batch we certify follows a rigorous, auditable pathway, aligned with EU GMP and regulatory standards. Learn more about our broader EU Import & Batch Release services and integrate Annex 16 certification seamlessly into your EU market access strategy.
Annex 16 certification is a regulatory requirement under EU GMP that ensures each batch of a medicinal product released into the European market is compliant, safe, and of consistent quality. The process is legally defined, requiring a Qualified Person (QP) to certify that the batch has been manufactured according to the Marketing Authorisation and EU GMP standards.
The role of the QP in Annex 16 is critical. QPs review manufacturing and quality documentation, evaluate test results, and confirm that all regulatory requirements are met before granting approval for batch release. This ensures that only compliant products enter the EU market and that regulatory accountability is maintained at every step.
Annex 16 certification operates within the broader EU GMP framework, covering documentation traceability, audit readiness, and adherence to manufacturing standards. By following this structured process, companies maintain compliance with EU regulatory expectations and can demonstrate inspection readiness.
It is important to note what our Annex 16 certification service does not cover. It is not import licensing, not a storage or distribution service, and not a general GMP consultancy. Its sole purpose is legally responsible batch certification, ensuring each product meets EU standards before market release.
Partnering with Inglasia for your Annex 16 certification provides a transparent, auditable, and compliant pathway, giving you confidence in the quality, legality, and market readiness of your medicinal products.
Inglasia’s Annex 16 certification service follows a structured, stepwise process to ensure that every batch meets EU GMP standards and is fully compliant before release.
Every batch begins with a thorough review of manufacturing and quality records. Our team verifies your production logs, test results, certificates of analysis, and all supporting documentation to confirm compliance with the Marketing Authorisation and EU GMP requirements.
Next, the batch undergoes a detailed technical evaluation. This step confirms that all production processes, testing outcomes, and deviations are documented and addressed. This includes technical compliance checks and verification, ensuring batches are EU importation tested by our Qualified QC Vendors. Any discrepancies are identified and resolved to ensure the batch meets regulatory expectations.
Qualified Persons conduct the formal certification, assuming legal responsibility for the batch. They confirm that your product complies fully with EU GMP and Annex 16 standards, providing a legally recognised authorisation for release.
Once certified, your product batch is approved for the EU market. This ensures downstream supply chain processes, including distribution or clinical supply, can proceed without regulatory risk.
This stepwise approach provides clarity, accountability, and commercial confidence. By structuring Annex 16 certification in this way, Inglasia ensures that every batch is fully documented, technically compliant, and legally authorised for the European market.
Contact us now
Under EU law, every batch of a medicinal product released into the market must be certified by a Qualified Person (QP). This legal responsibility is central to Annex 16 certification and ensures that regulatory accountability rests with the QP for every batch.
At Inglasia, every batch is certified under full regulatory accountability, meaning our QPs formally assume legal responsibility for compliance with EU GMP standards. This includes verification of manufacturing records, technical assessments, and all quality documentation before approval. Our process ensures that each batch meets both the Marketing Authorisation and EU regulatory requirements before it enters the European market.
This framework provides risk mitigation and compliance assurance. By maintaining detailed records, structured review processes, and inspection-ready documentation, our QPs reduce the likelihood of regulatory issues, product recalls, or non-compliance penalties. Every batch benefits from clear accountability, thorough evaluation, and legally recognised certification.
Partnering with Inglasia for Annex 16 certification ensures that your products are handled with precision, backed by legal authority, and released under a robust compliance framework, giving your business confidence and regulatory security for EU market entry.
Annex 16 certification operates within the framework of EU Good Manufacturing Practice (GMP), which defines the standards for quality, safety, and traceability of medicinal products. Compliance with the GMP ensures that every batch is produced under controlled conditions, thoroughly documented, and consistently meets regulatory requirements before release.
Our Annex 16 process aligns directly with inspection readiness and traceability requirements. Each batch undergoes a comprehensive review of production records, test results, and quality documentation, ensuring full transparency and auditability. This alignment allows for smooth inspections by regulatory authorities and supports the legal accountability of Qualified Persons responsible for certification.
By adhering to EU GMP standards, we reinforce the integrity of your medicinal products and maintain full regulatory compliance. Every batch released is traceable, technically validated, and fully documented, providing confidence to manufacturers, sponsors, and distributors that your product meets all EU legal and quality obligations.
Integrating Annex 16 certification with our broader EU Import & Batch Release services creates a seamless compliance pathway from import to market release. This ensures that your products are not only legally certified but also managed under a robust, inspection-ready, and GMP-aligned process from start to finish.
Inglasia offers a comprehensive suite of Annex 16 certification services, designed to ensure that every medicinal product batch entering the EU market is fully compliant, technically verified, and legally certified.
We provide legally recognised certification for commercial batches, confirming that each product meets EU GMP standards and the conditions of its Marketing Authorisation. Every certification is performed by an experienced Qualified Person, ensuring full regulatory accountability and inspection readiness.
Each batch undergoes a thorough technical assessment. Our team evaluates production processes, analytical testing, and quality deviations to ensure all requirements are met. This verification step guarantees that only compliant batches progress to certification, minimising regulatory and operational risk.
Complete and accurate documentation is essential for Annex 16 compliance. Inglasia reviews all manufacturing and testing records, certificates of analysis, and supporting documents. Once verified, the Qualified Person formally approves the batch for EU market release, ensuring traceability, transparency, and legal compliance.
By combining these services, Inglasia provides a fully integrated Annex 16 certification pathway. Every step is structured, auditable, and aligned with EU regulatory standards. Companies benefit from a seamless process that reduces risk, supports inspections, and ensures that your products are ready for market entry.
Learn more about our broader EU Import & Batch Release services and see how Annex 16 certification integrates into a complete, compliant pathway for your medicinal products. Partnering with Inglasia ensures regulatory certainty, technical precision, and legal accountability at every stage.
Inglasia’s Annex 16 certification services are designed for companies that require legally compliant, inspection-ready batch certification within the EU.
This includes non-EU Marketing Authorisation Holders (MAHs) seeking to release products into the European market under full regulatory compliance. Virtual pharma companies and biotech sponsors also rely on our services to ensure their batches meet EU GMP standards before market entry.
Contract manufacturers benefit from our structured processes, allowing them to certify each batch efficiently while maintaining traceability and accountability. Any company releasing medicinal products commercially or for clinical supply in the EU can rely on Inglasia to manage the regulatory, technical, and documentation requirements for Annex 16 compliance.
By partnering with us, you gain access to a regulated, accountable pathway that ensures every batch is certified under the supervision of experienced Qualified Persons, ready for inspection, and fully compliant with EU law. Our services give companies confidence that their products meet the highest standards of quality, safety, and traceability before reaching the European market.
Companies choose Inglasia for Annex 16 certification because our services combine legal authority, technical expertise, and compliance-driven processes. Our team of experienced Qualified Persons (QPs) ensures that every batch released under Annex 16 is fully inspected, verified, and certified according to EU GMP standards. Each certification is legally binding, placing regulatory accountability squarely on the Qualified Person and providing clients with confidence that their products meet all EU requirements.
Our processes are designed to be inspection-ready. Every batch undergoes thorough documentation review, technical assessment, and compliance verification, ensuring traceability and adherence to regulatory expectations. This structured approach minimises risk and safeguards against non-compliance, product recalls, or inspection issues.
Our clients benefit from a transparent, accountable certification pathway. From batch verification to final QP approval, every step is carefully managed to maintain full regulatory compliance. By handling the legal and technical responsibilities of Annex 16, we provide a secure, reliable, and auditable process that companies can trust.
Partnering with us ensures your batches are certified under a robust compliance framework, giving you confidence, risk control, and full regulatory assurance before products enter the European market. Learn more about our broader EU Import & Batch Release services to integrate Annex 16 certification seamlessly into your EU market access strategy.
EU GMP Annex 16 is the regulatory framework that defines how medicinal product batches must be certified before being released to the European market. It outlines the responsibilities of the Qualified Person and ensures that each batch meets strict quality, safety, and compliance standards.
Annex 16 certification involves a structured review of batch documentation, manufacturing records, testing results, and compliance with the Marketing Authorisation. The process ensures that all regulatory requirements are met before a batch is approved for EU market release.
General GMP covers the overall standards for manufacturing and quality control, while Annex 16 specifically governs the certification and release of individual batches. It focuses on the final verification and legal approval required before a product enters the EU market.
Yes. Any medicinal product intended for the EU market must undergo certification in line with Annex 16 requirements. This ensures that every batch is reviewed, verified, and approved under a consistent regulatory framework.
Annex 16 requires full documentation, traceability, and structured review processes for every batch. This ensures that all certification decisions are auditable and inspection-ready, helping companies demonstrate compliance to regulatory authorities.
Ensure every batch entering the EU market is fully compliant, certified, and inspection-ready with our Annex 16 Certification services. As your EU batch release partner, we provide legally accountable certification under EU GMP, supported by experienced Qualified Persons and structured, auditable processes.
Take the next step in securing regulatory compliance and market access for your medicinal products. Contact our team today to discuss your batch certification needs or schedule a consultation. We guide you through the pathway from documentation review to QP approval, ensuring every batch meets EU standards before release.
Learn more about how our EU Import & Batch Release services integrate with Annex 16 certification to provide a seamless, fully compliant EU market entry solution. Partner with Inglasia and release your products into the European market with confidence, accountability, and regulatory assurance.
